A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).
Epistemonikos ID: 2205ee91d0501464440b0744757e234bd74cbba8
First added on: May 10, 2024